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ABSTRACT. Bovine spongiform encephalopathy (BSE) created a global European crisis in the
1980s and 90s, with very serious health and economic implications. Classical BSE now appears to be
under control, to a great extent as a result of a global research effort that identified the sources of
prions in meat and bone meal (MBM) and developed new animal-testing tools that guided policy.
Priority (www.prionpriority.eu) was a European Union (EU) Framework Program 7 (FP7)-funded
project through which 21 European research institutions and small and medium enterprises (SMEs)
joined efforts between 2009 and 2014, to conduct coordinated basic and applied research on prions
and prion diseases. At the end of the project, the Priority consortium drafted a position paper (www.
prionpriority.eu/Priority position paper) with its main conclusions. In the present opinion paper, we
summarize these conclusions.
With respect to the issue of re-introducing ruminant protein into the feed-chain, our opinion is that sus
taining an absolute ban on feeding ruminant protein to ruminants is essential. In particular, the spread
and impact of non-classical forms of scrapie and BSE in ruminants is not fully understood and the
risks cannot be estimated. Atypical prion agents will probably continue to represent the dominant
form of prion diseases in the near future in Europe. Atypical L-type BSE has clear zoonotic potential,
as demonstrated in experimental models. Similarly, there are now data indicating that the atypical
scrapie agent can cross various species barriers. More epidemiological data from large cohorts are nec
essary to reach any conclusion on the impact of its transmissibility on public health. Re-evaluations of
safety precautions may become necessary depending on the outcome of these studies.
Intensified searching for molecular determinants of the species barrier is recommended, since this bar
rier is key for important policy areas and risk assessment. Understanding the structural basis for
strains and the basis for adaptation of a strain to a new host will require continued fundamental
research, also needed to understand mechanisms of prion transmission, replication and how they
cause nervous system dysfunction and death. Early detection of prion infection, ideally at a preclini
cal stage, also remains crucial for development of effective treatment strategies.
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The Priority Position
About 30 y ago, the appearance of BSE in
the United Kingdom (UK) quickly brought
the previously obscure “prion diseases” into
the public spotlight. The ensuing health and
food crises that spread throughout Europe
had devastating consequences. In the UK
alone, there were more than 36,000 farms
directly affected by BSE and the transmis-
sion of BSE prions to humans via the food
chain has caused over 200 people, most of
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them in Europe, to die from variant Creutz-
feldt-Jakob disease (vCJD).1
Classical BSE now appears to be under con-
trol, with 18 EU member states having achieved
the World Organization for Animal Health
(Office International des Epizooties) ‘negligible
risk’ status2 and the remaining member states
assessed as presenting ‘controlled’ risk. Of note,
research, including EU-funded research, has
played a key role in this success: while the ori-
gin of the infection was never defined, the prin-
cipal driver of the epidemic was identified as
prions in MBM.3 Tests based on the use of
prion protein-specific antibodies were devel-
oped, allowing detection of infected carcasses,
and a better understanding of disease pathogene-
sis and the distribution of infectivity in edible
tissues, and experimental investigation of trans-
mission barriers between different species
allowed an estimation of risks.4 All of this led
to the implementation of rational and effective
policies, such as the MBM ban to protect the
animal feed chain, and the Specified Risk Mate-
rial (SRM) regulations to protect the human
food chain (see reference 5 for an update on rel-
evant EU legislation5).
In spite of this progress, prions are still a threat.
Epidemiological re-assessment, and data on late-
onset kuru in 129M/V heterozygous PRNP car-
riers,6 indicate that the period separating the peaks
of the BSE and the vCJD epidemic (»10 years) is
probably too short to include potential late-onset
vCJD.7-8 In addition, results from a large number
of human tonsil and appendix analyses in the UK
suggest that there may be a high number of
asymptomatic individuals who are positive for the
disease-associated prion protein conformer,
PrPSc.10 While vCJD is the only form of human
prion disease that has been consistently demon-
strated to have lymphoreticular involvement,
there has been no systematic investigation of lym-
phoid tissue in humans with other prion diseases.
The Human Prion Problem
The clinical cases of vCJD identified to date
have all shared a common prion protein (PrP)
genotype, M129M, although one pre-clinical
case was confirmed as an M129V heterozygote,
and it has been mooted that perhaps only the
M129M proportion of the population is suscep-
tible. However, in the UK appendix study, PrP
accumulation was described in samples repre-
senting every codon 129 genotype. This raises
the possibility that PRNP genotype does not
confer resistance but instead modulates incuba-
tion period.10
Recent experiments in highly susceptible
mouse models indicate the presence of infectiv-
ity in blood or blood components at late disease
stages in sporadic CJD.11 The significance of
this experimental finding for humans has to be
explored in more detail, although, at the present
time, there is no evidence for the transmission
of prions via blood in sporadic CJD. However,
a likely scenario is that all cases with signs of
infection or abnormal PrP accumulation in
peripheral tissue could have infective blood,
posing the risk for transmission via blood prod-
ucts, and this has been clearly demonstrated in
experimental models,12 and confirmed in sev-
eral cases of vCJD in humans.9,13 Altogether,
these data clearly demonstrate the potential risk
of a second, late-onset wave of vCJD, particu-
larly when the number of people identified with
lymphoid accumulation of PrPSc (16/32411)
gives a prevalence estimate in the UK of 493
per million, much higher than the number of
clinical cases seen to date.
The Animal Prion Problem
An increasing number of reports of cases of
“atypical” BSE in cattle throughout the EU and
beyond, in part a reflection of increased testing
and awareness, may be a forewarning of a new
epidemic, particularly since we still do not
understand all the factors determining the spe-
cies barrier. Ovine scrapie is another concern,
because it could mask ovine BSE, presumably
transmissible to humans. While ovine scrapie
and BSE can be analytically told apart post-
mortem, differentiation is not easy in live ani-
mals– the clinical sign differences being very
subtle.14 Scrapie is endemic and not likely to
be eradicated soon, although current control
measures are effective at greatly reducing dis-
ease incidence. Atypical forms, which may be
spontaneous, are not affected by these control
measures and they will persist in the global
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animal population. These disease forms now
predominate, and effective surveillance is very
challenging, in part as a consequence of the
absence of clusters, which makes their identifi-
cation rather demanding in terms of labor and
costs. Atypical cases of BSE and scrapie pres-
ently clearly outnumber classical cases in cattle
and sheep in many member states. There is a
clear risk attendant on ignoring these cases with-
out an understanding of their possible zoonotic
potential, or their potential to become an animal
health problem should current feed controls be
relaxed, particularly when most forms of human
disease have no established etiology.15
The Priority Project
The Priority project was launched in Sep-
tember 2009. A Large Integrating Project
within the EU FP7, its immediate objective was
to “protect Europe’s food chain from prions,”
while its wider scope was to understand prions
by using basic and applied research. Priority
focused on 4 themes, namely: a) the structure,
function, conversion and toxicity of prions; b)
detection of prions; c) mechanisms of prion
transmission; and d) spreading and epidemiol-
ogy of prion diseases. The project ended in
September 2014. Research associated with the
project has resulted in publication of more than
100 scientific papers (www.prionpriority.eu),
and the elaboration of a Position paper with the
main conclusions of the consortium at the end
of the project. The current paper summarizes
the opinions/positions reached within these
themes at the end of the project. The full Prior-
ity position paper can be found in: www.prion
priority.eu/Priority position paper.
PRION STRUCTURE, FUNCTION,
CONVERSION AND TOXICITY
The mechanisms for conversion of the nor-
mal cellular prion protein, PrPC to PrPSc, as
well as strain diversity and transmission bar-
riers, are structurally enciphered.16,17 There-
fore, it is essential to understand the structure
of PrPSc in order to design methods to interfere
with prion propagation and spread.
PrPSc forms double amyloid fibers made up
of 2 intertwined fibrils, each »3–5 nm wide,
with no regular pitch. Fiber X-ray diffraction
data, cryo-EM analysis and geometric consider-
ations strongly suggest that each PrPSc mono-
mer stacked in each protofilament is a 4-rung
b-solenoid, with a high structural resemblance
to the HET-s fungal prion.18,19 Limited proteol-
ysis studies corroborate that PrPSc contains
stretches of high resistance to proteinase K
(PK), presumably b-strands, interspersed with
short stretches with a higher proteolytic suscep-
tibility, presumably loops and turns.20 The C-
terminal stretch (»180–231) is the most PK
resistant region, arguing that no residual a-heli-
cal structure remains in PrPSc.20 While this
knowledge of the structure of PrPSc is still far
from complete, it allows us to hypothesize how
propagation of PrPSc might occur: templating
must involve the upper- and lowermost rungs of
the b-solenoid. These edge strands are “sticky;”
they will propagate their hydrogen-bonding pat-
tern into any amyloidogenic peptide they
encounter.21 In fact, the b-strands of native pro-
teins based on a b-solenoid motif have evolved
to contain capping loops and other structures to
block unregulated stacking. Furthermore, the
elimination of the capping structures results in
edge-to-edge driven oligomerization.22 Thus,
the upper and lower b-solenoid rungs could
template an incoming unfolded PrP molecule,
creating additional b-solenoid rungs. Once the
initial additional b-rung has formed, it creates a
fresh ”sticky” edge ready to continue templating
until the whole incoming unfolded PrP molecule
is fully converted into another copy of the infec-
tious conformer, i.e., a complete 4-rung sole-
noid stacked on its template.
It is noteworthy that the molecular forces
responsible for the templating, i.e., hydrogen-
bonding, charge interactions, aromatic stacking,
and steric constraints, are fundamentally similar
to those operating during DNA replication. Obvi-
ously, the exquisite specificity of the A:T and G:C
pairings is lacking and instead, a muchmore com-
plex array of forces controls the pairing of the pre-
existing and nascent b-rungs.
Unraveling the early events in structural
prion formation in sporadic forms of prion dis-
ease is of major importance, since the
168 J. R. Requena et al.
conversion of PrPC to PrPSc is the central event
in prion diseases. Hereditary prion diseases are
associated with about 40 point mutations of the
PRNP gene that codes for PrP. Most of the var-
iants associated with these mutations are
located in the globular domain of the protein.23
Opinions-Positions
The basic tenet of the prion theory, i.e. that
protein misfolding can be faithfully propagated,
is now widely accepted. Moreover, novel data
increasingly implicate similar “prionoid” prin-
ciples in the pathogenesis of “proteinopathies”
such as Alzheimer’s, Huntington’s and
Parkinson’s disease.24,25 In sharp contrast to
this fundamental understanding, and despite
the development of many new tools for prion
research, the most basic mechanistic details of
how prions function and how they cause dis-
ease have not been completely solved yet.
Major Questions and Scientific
Challenges
Many aspects of prion replication can be dem-
onstrated in vitro in cell-free systems containing
PrPC and PrPSc.26 At first approximation, prion
propagation can thus be reduced to a biophysical
problem dealing with alternative conformations,
amyloid structures, and conformational coer-
cion.19 However, like other pathogens, prions
maintain a complex, 2-way relationship with the
host cell. It is clear that prions propagate in their
natural hosts much more efficiently than they do
in vitro.27 The host cell provides both the molecu-
lar species (such as PrPC) and the molecular
mechanisms required for prion propagation.
Although nowwe are beginning to understand the
molecular underpinnings of (i) the uptake of
prions by the host cell and relevance of intracellu-
lar pathways for prion conversion, (ii) the influ-
ence of host cell signals and factors on prion
replication, (iii) the normal function of the prion
protein and pathogenesis, i.e., mechanisms by
which prions cause dysfunctions or damage to the
neurons, and (iv) the transfer of prions to neigh-
boring cells, there is still much to cover in these
areas.
Regarding the role of intracellular trafficking in
prion diseases, amyloidic prion structures called
“strings” containing PrPSc are found on the sur-
face of infected cells,28,29 while the endosomal
compartment is also strongly implicated in prion
conversion.30 Furthermore, novel structures called
tunneling nanotubes (TNTs) appear to have a
major role in spreading PrPSc between cells in cul-
tures,31 however better tools are needed to demon-
strate their presence and role in vivo.32
One major scientific challenge is to better
understand the structural basis of the different
prion strains and the mechanisms behind the
transmission barriers between animal species.
However, we are now in a position to state that
strains are specific molecular topologies of the
upper and lower surfaces of PrPSc monomers in a
propagative PrPSc stack (either oligomer or proto-
filament in a fiber); in turn, transmission barriers
consist of steric hindrances hampering continua-
tion of the cross-b stack by preventing an incom-
ing PrP strand from being molded onto the
pre-existing PrPSc assembly.19 Related to this is
the question of why some prions are more patho-
genic than others for humans. An additional chal-
lenge will be to investigate age-related factors that
promote development of sporadic prion diseases,
since these mainly affect aging people (average
age of onset is around 65 y old). Another major
effort to understand basic mechanisms of the dis-
ease would be required to develop adequate and
early therapies for humans affected by the dis-
eases. This input can only come from the scientific
community because there is a clear lack of indus-
trial investment to study and develop compounds
for the treatment of CJD affected individuals.
Strategic Objectives and Priorities in the
Future
 More data of a higher resolution are
needed to understand the structural basis
of prion strain transmission barriers, e.g.
by NMR-based, deuterium exchange anal-
yses of recombinant PrPSc.
 Structural analysis of the various point muta-
tions present in the globular domain of PrPSc
should unveil common folding traits that
may allow a better understanding of the early
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conformational changes leading to the for-
mation of monomeric PrPSc.
 Analyses should be carried out combining
high resolution imaging tools and neuro-
physiology that leads to a better under-
standing of the function of the prion
protein and the intercellular transmission
of its pathological isoforms.
 Analyses of the cause of prion toxicity and
identification of host cell-derived factors
that are “partners in crime” should provide
novel strategies aimed at blocking prion
propagation and toxicity.
 Treatment strategies for individuals
affected by CJD and of prophylactic
approaches for carriers of pathogenic
PRNP mutations should be developed.
PRION DETECTION
Post mortem detection systems for PrPSc in the
central nervous system (CNS) and lymphoreticu-
lar tissue are nowadays widely used for surveil-
lance of BSE and scrapie in animals.33 These
rapid tests have greatly improved the detection of
infected carcasses before their entry into the
human food chain. Lately the development of
highly sensitive methods like protein misfolding
cyclic amplification (PMCA) and real time quak-
ing induced conversion (RT-QuIC) made it possi-
ble to detect even minor amounts of PrPSc in body
fluids like blood or cerebrospinal fluid.34 Even
though these tests still need to be improved to
allow widespread use in routine laboratories, their
robustness has been demonstrated. They open up
newways for live tests to detect prions.35
Opinions-Positions
The emergence of in vitro amplification tech-
nologies such as PMCA and RT-QuIC represents
a real revolution for prion detection. These tech-
niques display sufficient sensitivity to allow
prion detection in the body fluids (such as blood
and cerebrospinal fluid) collected from affected
individuals, and their ability to do this has been
demonstrated in both sheep and human sam-
ples.34 However, at the moment they remain of
limited robustness and the mechanisms and
analytical conditions which allow amplification
of misfolded PrP remain largely unknown. Such
issues are similar to those encountered when
PCR was developed in the 1980s. Despite those
initial difficulties PCR is now a basic research
laboratory technique.
Prions may also be considered as potential
environmental contaminants and their stability
in the environment, wastewater and soils must
be evaluated as a valuable parameter for devel-
oping risk assessment studies. Prions are
extremely resistant to inactivation and it has
been demonstrated that they can survive in soil
for years.36,37 In recent years, deposition of
scrapie and chronic wasting disease (CWD)
infectivity in the environment through biologi-
cal fluids and/or faeces has been proved,38 and
BSE and scrapie can also be introduced anthro-
pogenically by transporting infectious prions
via landfill leach or slaughterhouse wastewa-
ter.39,40 All of this strongly suggests that infec-
tious prions can enter the environment, and
could be transported via water, resulting in
exposure of both humans and animals to infec-
tious prion diseases. Therefore, it is critical to
adapt and develop analytical methods and strat-
egies to evaluate the fate of infectious prions in
the environment and the potential sources of
contamination.40,41
Major Questions and Scientific
Challenges
Amajor scientific challenge is to develop new,
and refine existing, prion detection methods that
could have applications in pharmaceutical screen-
ing, consumables testing, environmental monitor-
ing (e.g., allowing re-population of previously
affected farms), and in vivo diagnostics.
The behavior and stability of prions in the envi-
ronment and wastewater have to be better defined,
and the efficiency of wastewater treatments for
the removal of prions needs to be assessed.
Strategic Objectives and Priorities in the
Future
 Improving the performance and robustness
of in vitro prion amplification techniques.
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 Establishing a relationship between the
presence of PrPSc, as demonstrated in an
environmental matrix by in vitro amplifi-
cation methodology, and the risk of prion
transmission for an individual that would
be exposed to such a matrix.
 Redefining the techniques available to
optimize the detection of prions in diverse
environmental matrices, with validated
protocols.
PRION TRANSMISSION AND
SPREADING
Following peripheral exposure, some
acquired prion strains accumulate and replicate
in the secondary lymphoid organs (SLO) such
as the gut-associated lymphoid tissues (GALT)
in the gastrointestinal tract. This amplification
stage in the SLO is critical for the efficient
spread of these prion strains to the central ner-
vous system through a process termed neuroin-
vasion. In the past 15 y there has been
intensive research into this early phase of the
disease process.42,43 Identification of the impor-
tant cellular and molecular processes required
for the establishment of prion infection in the
GALT and subsequent neuroinvasion has
implications beyond academic interest, as
experiments have shown that treatments that
block this process can dramatically reduce sus-
ceptibility to peripherally-acquired prions.44,45
Indeed, the demonstration that vCJD in humans
most likely arose due to consumption of BSE-
contaminated food has focused attention on
whether immunotherapeutic approaches, such
as anti-prion vaccines, may represent a valid
therapeutic strategy against prion infection.46
Opinions-Positions
Although control measures have helped to
limit further spread of BSE in Europe, prions
continue to pose important health, welfare and
economic problems to the livestock industry
worldwide and have direct consequences for
human health. Countries outside Europe are
reporting BSE cases, and novel BSE variants
with uncertain transmission potential have been
described. BSE has also been identified in
goats, raising concern that it may have infected
sheep.47,48 Little is known of the mode of trans-
mission of CWD in North America and the
consequences to livestock and human health.
The transmission potential of atypical forms of
sheep scrapie is also uncertain. Many important
questions remain concerning the pathogenesis
and modes of transmission of prion diseases in
animals and humans. The lack of prion-specific
preclinical diagnostics compounds the prob-
lems for disease identification, treatment and
eradication. Since future outbreaks of prion dis-
ease are likely to be orally-acquired, a thorough
analysis of the factors that influence suscepti-
bility to orally-acquired prions will enhance
our understanding of the factors which increase
the risk of disease transmission, improve pre-
clinical diagnosis and help identify novel
targets for prophylactic and therapeutic
intervention.
A unique subset of stromal cells within the
B-cell follicles of secondary lymphoid tissues,
termed follicular dendritic cells (FDC), are con-
sidered to be the essential early sites of prion
accumulation and replication.44,45,49 Data from
experimental scrapie prion transmissions to
mice show that initial replication in the GALT
of the small intestine such as the Peyer’s
patches is critical for efficient neuroinva-
sion.50,51 As well as expressing high levels of
cellular prion protein, these cells trap and retain
the prions on their surfaces, where they are
amplified above the threshold level required
to achieve infection of local peripheral
nerves.49,52-54 However, the requirement for
initial accumulation and replication on FDC is
not absolute. Under certain circumstances
some prion strains or isolates may accumulate
in lymph nodes in association with high endo-
thelial venules independently of FDC.55 Also,
some prion strains such as BSE appear to
achieve neuroinvasion from the gastrointestinal
tract without any apparent amplification step in
the GALT.
Following their amplification within the
SLO, prions subsequently infect the peripheral
nerves within these tissues and spread along
them to the CNS.56,57 How prions initially
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spread from the FDC and infect the peripheral
nervous system is uncertain. A role for classical
dendritic cells in this process has been pro-
posed in which these cells may shuttle prions
between FDC and nearby peripheral nerves.58
Alternatively, tunnelling nanotubes which
extend and connect cells may act as intercon-
necting conduits through which prions may be
transferred between cells.31
The demonstrations that immune cells
played an important role in the establishment
of prion infections, and that prions were present
in significant burdens in the SLO for the dura-
tion of the preclinical phase,59 suggested that
vCJD had the potential to be accidentally trans-
mitted horizontally between humans via the
transfusion of blood or blood products from an
infected individual.9 As a consequence of these
findings, procedures such as leukodepletion
were introduced in an attempt to reduce the
potential for vCJD to be transmitted via the
transfusion of blood or blood products.
Sites of chronic inflammation, by inducing
the formation of ectopic FDC-containing B-cell
follicles or granulomatous lesions, might influ-
ence the organ tropism of prions and induce or
enhance local prion infectivity of tissues that
otherwise would not be considered at risk.60,61
The detection of disease-specific PrP in mam-
mary glands from lentivirus/prion co-infected
ewes warned about the potential exposure of
humans to prions through the consumption of
small ruminant milk. Sheep with scrapie and
lentiviral mastitis accumulate prions within the
ectopic follicles in the inflamed mammary
glands. Importantly, these sheep also secreted
levels of prions in their milk which were suffi-
cient to transmit disease to suckling lambs.62
Subsequent studies in non-mastitic goats and
sheep have since suggested that milk and colos-
trum may transmit classical scrapie from an
infected ewe to their offspring.63-65 Together,
these elements called for an urgent understand-
ing of potential prion infectivity levels associ-
ated with ruminant blood and milk.
The consumption of BSE-contaminated meat
products is the most likely source of vCJD in
humans.66 During the BSE epidemic in the UK it
is estimated that up to approximately 500,000
infected cattle were slaughtered for human
consumption.67 Surprisingly, despite the likely
widespread exposure of theUKhuman population
to BSE prions, most clinical cases of vCJD have
occurred almost exclusively in young adults
(median age at onset of disease, 26 years; median
age at death, 28 years). The factors responsible
for the age-related incidence of vCJD are uncer-
tain as the possibility that young adults were
exposed to greater levels of BSE by dietary prefer-
ence is unproven.68 Data from experimental prion
transmissions to mice suggest that the effects of
aging on the microarchitecture of SLO dramati-
cally reduce susceptibility to peripherally-
acquired prion disease.69-72
Major Questions and Scientific
Challenges
After ingestion, BSE prions in cattle appear
to be able to infect the nervous system indepen-
dently of consistently detectable replication
within the GALT. The rules which govern this
for BSE and other prion isolates are currently
uncertain, since oral transmission of BSE
prions to other species appears dependent on
agent replication in the GALT prior to neuroin-
vasion. An ability to predict the transmission
characteristics following the identification of a
novel prion isolate will be important for assess-
ing human and animal health risks.
Much progress has been made in our under-
standing of how prions are initially conveyed
from the site of exposure to cells within the
SLO upon which they replicate.42,43,73 For
example, after oral exposure prions may cross
the gut epithelium via M cells to infect the
Peyer’s patches.74,75 How prions subsequently
infect the FDC within the B-cell follicles is
uncertain, but a role for classical dendritic cells
in this process has been considered.56,76
Once the prions have been amplified on the
surfaces of FDC above the threshold required
for neuroinvasion, they infect the enteric nerves
within the intestine,56,77 and spread via the
peripheral nervous system (both sympathetic
and parasympathetic) to the CNS.78,79
Although the relative positioning of the FDC
and sympathetic nerves within the SLO appears
to influence the rate of neuroinvasion, the
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precise mechanism by which this occurs is
uncertain.
The transmission of prion strains within the
same host species is typically efficient and
causes disease in the recipients with highly
reproducible disease characteristics. However,
inter-species prion transmissions upon first pas-
sage are typically characterized by their low
efficiency and extended disease incubation
periods. This effect on prion transmission is
termed the ‘species barrier’ effect. Many fac-
tors are known to have an important influence
on the inter-species transmission of prions such
as polymorphisms and mutations in the PRNP
gene (which encodes PrPC), and biophysical
aspects of templating events are clearly impor-
tant (see above). Unfortunately the precise
molecular mechanism/s responsible for the spe-
cies barrier effect is uncertain. An ability to
predict the potential for a novel prion isolate to
have the potential to transmit to other species,
especially humans, is crucial to restrict and
control future prion disease outbreaks.80
Pioneering studies have shown that both pas-
sive and active immunization against PrP are
feasible approaches to attempt to block experi-
mental prion diseases.81,82 Many natural prion
infections are orally acquired, and mucosal vac-
cination against prions appears to be effective
and the most appropriate method for protection
against orally acquired prion infections.83
However, a mucosal vaccine may offer little
protection against accidental iatrogenic CJD
transmissions via contaminated blood or blood
products, tissues or contaminated surgical
instruments. Therefore, an ideal anti-prion vac-
cine should be able to induce both strong muco-
sal and systemic anti-PrP antibody responses.
However, the cellular prion protein is almost
ubiquitously expressed in the mammalian host,
and so the potential for any anti-prion vaccines
to bind to host PrPC and cause autoimmunity or
cell toxicity must be carefully considered. A
recent study has provided valuable information
on the factors which influence the ability of
anti-prion antibodies to cause rapid neurotoxic-
ity.84 These data suggest it may be possible to
identify those vaccines which induce the devel-
opment of potentially neurotoxic anti-PrP
antibodies.
Strategic Objectives and Priorities in the
Future
 Thorough characterization of the cellular
relays by which prions are propagated
from peripheral sites of exposure to the
central nervous system should be carried
out.
 Determination of the factors which control
prion replication in SLO, and why this is
obligatory for the efficient neuroinvasion
of some, but not all, prion strains.
 Determination of the molecular character-
istics, other than PrPC expression, which
render cells such as FDC susceptible to
prions.
 Identification of the mechanisms involved
in cell-to-cell prion spreading.
 Assessment of how prions are released into
body fluids and how this may contribute to
their contamination of the environment,
and their transmission between hosts.
 Development of effective immunothera-
peutic strategies to protect the host against
peripherally acquired prions, and a better
understanding of when to target these
strategies based on host age/species.
 Understanding of the underlying factors
which determine the species barrier effect,
to enable the prediction of the risks to
human and animal health posed by novel
prion strains.
 Development of a highly sensitive and
specific diagnostic test to identify prion-
infected individuals from the early pre-
clinical stages of disease, and gaining of a
more accurate understanding of preva-
lence of these diseases in populations.
 To enable the above to be achieved effi-
ciently, it will be important to establish
consistent protocols and experimental
models to enable meaningful comparisons
to be made between studies generated in
different laboratories.
PRION EPIDEMIOLOGY
In recent years considerable disease control
efforts have been made by the EU to control
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prion infections in cattle, sheep and goats
through the implementation of rigorous
regimes. An array of regulations such as the
introduction of the feed ban, a compulsory sur-
veillance and monitoring system, the removal
and destruction of SRM and the establishment
of culling strategies for small ruminants by
member state authorities have all had a signifi-
cant impact on the incidence and spread of
disease.
Undoubtedly, these measures have been
responsible for reducing the number of BSE
cases detected in the EU from 2,167 in 2001
(15 member states) to 68 cases in 2009, 44
cases in 2010 and down to 7 cases in 2013/14
(September 2014) in 27 member states.
CWD is a naturally-occurring prion disease
in domestic and wild cervids (moose deer and
elk), which has reached epidemic proportions
in the US and Canada.85 However, it has not
been detected in Europe so far, even though
there is significant trafficking of potentially
contaminated materials between continents.
The potential presence of CWD in Europe is
not continuously monitored, although there was
a single EU-wide cervid surveillance exercise
undertaken some years ago in the context of the
EU Regulations for BSE and scrapie, which
detected no cases. The deposition of scrapie
and CWD prions in the environment occurs
through biological fluids and/or faeces.39,86
Data depict a scenario where prions may accu-
mulate in the environment due to direct shed-
ding from pre-clinical animals, and remain
infectious in soil and water for periods of time
long enough to permit transmission to suscepti-
ble individuals.87,88 Thus CWD, unlike BSE is
horizontally and vertically transmitted among
captive and wild animals, so it is extremely dif-
ficult to eradicate. Given that both red deer and
reindeer are native to Europe, there is no reason
to assume that CWD could not become a prob-
lem in the European continent.
Although the scenario for BSE may not be
exactly the same (BSE prions are present at
much lower levels in extraneural tissues than
in the CNS), deposition of BSE prions in the
environment may occur due to burial of car-
casses and mortalities, and to a lesser extent,
through biosolids generated in water treatment
plants by the processing of infected animals
which had not been identified and removed.
Presumably this scenario occurred frequently
during the BSE epidemic. Furthermore, there
is the possibility of discharged contaminated
urine, feces and blood from CJD or vCJD
patients.89-91
In humans, several molecularly-defined dis-
ease subtypes have been described. 92-95 How-
ever, neither the molecular basis nor the
epidemiological significance of these so called
sporadic disease subtypes are understood.
Analysis of the genetic CJD-risk in the general
population, focused on the PRNP mutation
E200K, confirmed the occurrence of asymp-
tomatic (“healthy”) carriers of this mutation
without their known relation to CJD patients.
The first data on the overall most common
CJD-specific mutation in the general popula-
tion signal possibly an iatrogenic CJD risk, as
well as a hidden iatrogenic explanation in some
sporadic CJD cases.96
Opinions-Positions
A better understanding of the way in which
different strains of prions may spread between
animals and human beings, and the environ-
mental factors that modulate this, is essential to
help design methods for the prevention of the
spread of prions within communities. Improved
methods for decontamination and disposal of
animal waste as well as assessment of prions in
wastewater and soils are crucial to prevention
of the spread of prions.
Although still declining, BSE has not been
eradicated so far, and one might question if
eradication is generally achievable, particularly
when the potential for sporadic cases of BSE is
considered.97 The occurrence of these atypical
cases of BSE, in light of alleged new types of
atypical BSE in Germany (2013/14) and earlier
(2011) in Switzerland, would remain unde-
tected with any reduction in surveillance, and is
therefore a major point of concern.98 Further-
more, sporadic cases of BSE appear to be sig-
nificantly different from orally acquired BSE in
many aspects. The most obvious differences
in such atypical/sporadic BSE cases are the
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tendency for the diseased animals to be in the
last third of the life span for cattle, and to pres-
ent a different molecular phenotype of the prion
protein.99 Most recently (2013/2014), 2 new
cases of non-classical BSE were diagnosed in
Germany, a country where BSE had last been
seen in 2009. The overall picture of atypical/
sporadic BSE is complicated by the fact that
these 2 new cases of BSE appear to be different
from known atypical cases in cattle.
The occurrence of atypical BSE in older
cows with an extended pre-clinical phase poses
a particular challenge. Even in classical BSE,
depending on different testing scenarios, the
European Food Safety Authority (EFSA) has
published a report97 in which the surveillance
data indicate the possibility of missing BSE
cases in healthy or at risk animals. In the con-
sortium’s opinion the chance of spread of BSE
within the cattle population can be regarded as
negligible as long as the feed ban is still opera-
tive. Likewise, under the present regulatory
regimens the exposure risk for humans is very
low.
Cases of atypical scrapie in sheep and goats
as well as BSE in sheep and goats further com-
plicate the picture. The fact that in the years
2010 - 2014 (September 2014) atypical scrapie
has become the most common form of disease
detected in sheep in many countries causes
quite some concern. None of the breeding
measures implemented for disease control in
small ruminants have affected the prevalence
of atypical disease, despite being shown to be
effective for the control of classical scrapie,
because both the epidemiology of the disease
and the genetics of host susceptibility are dif-
ferent for classical and atypical scrapie.97
Prion diseases cannot be eradicated, espe-
cially the spontaneous diseases, and it is the
opinion of the consortium that a continuous
robust targeted surveillance of both animal and
human populations is still required.
Major Questions and Scientific
Challenges
Although the epidemiology of atypical TSE
cases supports the hypothesis of a spontaneous
origin, they can be experimentally transmitted
and therefore present a risk. Also the stability
of these prions upon passage is not yet known:
they may become more infectious following
either inter- or intra-species passage. A major
scientific challenge is therefore to understand
the basic biology and key components deter-
mining susceptibility and transmissibility.
More information about the susceptibility of
prions to inactivation treatments in wastewater
treatment plants and their stability relative to
environmental factors is necessary. Further
analysis would, thus, be necessary to under-
stand if improvements to increase biological
inactivation are a real solution for prion inacti-
vation in wastewater treatment plants.
Data have indicated that the inactivation of
infectious BSE in the environment cannot be
estimated only by the measurement of protease
resistant PrPSc levels. Improved PrP markers
must be defined to be used as target parameters
when considering infectivity.
Strategic Objectives and Priorities in the
Future
 Appropriate prion agent surveillance
should be maintained in both the animal
and human populations, and surveillance
tools should be reviewed, expanded and
developed according to the state of current
scientific knowledge, given the existence
of atypical prions in cattle and small rumi-
nants, which were unknown until recently,
and the new concept of “prionopathies” in
humans.
 Definition of suitable wastewater treat-
ments that would reduce the possibility of
prion dissemination in the environment
should be accomplished.
 Water samples impacted by infected ani-
mal excreta and wastewater should be ana-
lyzed for any potential role in the
transmission of prion diseases, producing
data on the potential dissemination of
prions in these areas.
 A study of the potential presence of CWD
in Europe, including a targeted surveil-
lance program for the detection of CWD
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prions and studies of their behavior in the
environment, should be implemented
 Development of programs for education
and awareness within farming communi-
ties and veterinary and medical personnel,
in particular, as a frontline surveillance,
should be carried out.
 Establishment of more comprehensive
continuous, molecular strain-defined sur-
veillance of all forms of human prion dis-
eases for early identification of atypical
cases and potential outbreaks in humans.
 Determination of the epidemiological risk
and the significance of the relatively large
number of asymptomatic carriers of
human PrPSc (tonsil, appendix studies)
 Strain-specific therapeutic options in clas-
sical and atypical CJD in humans should
be developed and defined.
CONCLUDING REMARKS
After the initial shock caused by the BSE cri-
sis, the scientific community reacted vigorously
and in a short period of time provided essential
knowledge and tools to policymakers and soci-
ety at large that were critical to curb, reverse
and eventually control the epidemic in cattle.
The decisive support and funding provided by
the EC to researchers in the prion field played a
key role in this endeavor. From our current van-
tage point, it is critical that policies based on
scientific knowledge that have proven to be
highly efficacious are not relaxed based on
short-sighted economic considerations. Fur-
thermore, research efforts need to be continued
(and funded) as important basic aspects of
prion biology still remain unsolved, despite
impressive advancements in recent years.
Beyond the obvious benefit of protecting the
food chain, prion biology is being increasingly
recognized as relevant to the understanding of
a subset of neurodegenerative ailments, such as
Alzheimer’s and Parkinson’s diseases that kill
millions every year.25 Knowledge obtained
from the study of prions and prion diseases
might prove to be of enormous interest in the
near future not just to keep our food safe.
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